Follow-On Biologics Debate May Divide PhRMA On Comparability Protocols
This article was originally published in The Pink Sheet Daily
Executive Summary
PhRMA President Tauzin acknowledges “there’s a little difference of opinion” among membership about what the criteria for interchangeability should be.
You may also be interested in...
Senate Biosimilars Bill May Create Exclusivity For Pediatrics And Extra Indications, PhRMA Says
Sponsors are committed to firm 12 years of exclusivity, but evergreening remains an obstacle to reintroduction.
Senate Biosimilars Bill May Create Exclusivity For Pediatrics And Extra Indications, PhRMA Says
Sponsors are committed to firm 12 years of exclusivity, but evergreening remains an obstacle to reintroduction.
Genzyme Receives Complete Response, Warning Letters For Lumizyme
The hits just keep on coming for Genzyme. On a March 2 call with investors, the firm had to announce not just a "complete response" letter for its 2000-liter scale-up of Myozyme (which will be called Lumizyme for the larger production scale), but also that its Allston Landing manufacturing site had received a 483 report from FDA and a subsequent warning letter